Piperidolate

Summary

Piperidolate (CHEMBL1623992) is an approved small molecule (ATC A03AA30); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A03AA30
• Indications: 1 condition
• Chemistry: 323.4 Da · C21H25NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1623992
Name	Piperidolate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4839
ATC	A03AA30
Molecular formula	C21H25NO2
Molecular weight	323.4
InChIKey	KTHVBAZBLKXIHZ-UHFFFAOYSA-N

SMILES: CCN1CCCC(C1)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3

IUPAC name: (1-ethylpiperidin-3-yl) 2,2-diphenylacetate

Also known as: JB-305, Piperidolate, Piperidolato, SID11112284, PIPERIDOLATE, piperidolate, PIPERIDOLATE HYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL1511957

Patent coverage: 127 distinct patent families (399 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Cytochrome P450 2D6, Cytochrome P450 1A2, Cytochrome P450 3A4.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 6 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP1A2	8.9	AC50	1.26	nM	CHEMBL_ACT_6042772
CYP2D6	5.8	Potency	1585	nM	CHEMBL_ACT_4949872
CYP2D6	5.8	AC50	1585	nM	CHEMBL_ACT_6071470
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_4949612
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_5018533
CYP3A4	5	AC50	10000	nM	CHEMBL_ACT_6036094

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).